

## Changed number of shares in iZafe Group AB

**Stockholm, Sweden. iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) – a leading life science company in the digitalization of medication management decided in November 2018 on a warrant program, TO 6 B. The exercise period for the warrants of series TO 6 B took place during the period 14 May 2021 to 28 May 2021 and has thus been completed. A total of 7,974 TO 6 B was used for subscription, implying a utilization rate of approximately two percent.**

A total of 7,974 warrants were used, corresponding to approximately two percent of all issued warrants, for subscription of 7,974 Class B shares at a subscription price of SEK 2.60 per Class B share. Through the exercised warrants, iZafe Group will thus receive just over SEK 20 thousand before issue costs.

### **Number of shares and share capital**

Through the exercise of the warrants, the number of shares in iZafe Group will increase by 7,974 Class B shares, from 34,827,700 to 34,835,674 Class B shares. The share capital thereby increases by SEK 7,974, from SEK 35,427,700 to SEK 35,435,674.

The issue entails a dilution effect of the share capital of approximately 0.02 percent.

### **Contacts**

Thomas Ahlerup, Chairman of the board and Investor Contact

E-mail: [thomas.ahlerup@izafegroup.com](mailto:thomas.ahlerup@izafegroup.com)

Phone number: +46-7868-966 300

iZafe Group AB (publ.)

Södra Fiskartorpsvägen 20

114 33 Stockholm

E-mail: [ir@izafegroup.com](mailto:ir@izafegroup.com)

[www.izafegroup.com/investor-relations](http://www.izafegroup.com/investor-relations)

### **About Us**

iZafe Group is a Swedish med-tech company that develops and markets medical and digital security solutions to create safer drug handling at home. Our digital medicine dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. Our products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: [info@fnca.se](mailto:info@fnca.se). Further information is available at [www.izafegroup.com/investor-relations](http://www.izafegroup.com/investor-relations).

Press Release  
09 June 2021 14:50:00 CEST

---



## Attachments

---

[Changed number of shares in iZafe Group AB](#)